This first-in-human trial evaluates safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-514 as monotherapy and in combination with budigalimab (BDG), a PD-1–blocking antibody.

Mar 26, 2025 · About ABBV-514 ABBV-514 is an investigational anti-chemokine C-C motif receptor 8 (CCR8) antibody that is being investigated for the treatment of relapsed non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) both as a monotherapy and in combination with a PD-1 inhibitor. 2,7 About AbbVie AbbVie's mission is to ...

ABBV-514 is an anti-chemokine C-C motif receptor 8 (CCR8) antibody that is being investigated for the treatment of relapsed non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) both as a single agent and in combination with a PD-1 inhibitor.

4 days ago · ABBV-514: A Novel CCR8-Targeting Antibody. In another significant presentation, AbbVie will provide updates on ABBV-514, a cutting-edge CCR8-targeting antibody that is currently in Phase 1 trials for various solid tumors, including non-small cell lung cancer (NSCLC) and head and neck cancer. CCR8 is a promising immune-oncology target due to its ...

Budigalimab and ABBV-514 are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called treatment arms. The maximum-tolerated dose (MTD)/maximum administered dose (MAD) of ABBV-514 will be explored.

Mar 26, 2025 · Data from AbbVie's immuno-oncology platform highlight the potential of a novel CCR8-targeting antibody, ABBV-514, in driving anti-tumor immunity. 2 CCR8 is a promising target due to its enhanced ...

M24-122: A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

relapsed/refractory (R/R) solid tumors will be enrolled in ABBV-514 monotherapy (N 55) or ABBV-514 + BDG (N 55) cohorts; up to 30 additional patients will be included in paired biopsy cohorts.

In dose expansion, patients with R/R non-small cell lung cancer will be enrolled in ABBV-514 monotherapy (N=12) and ABBV-514 + BDG (N=12) cohorts, and patients with R/R head and neck squamous cell carcinoma in an ABBV-514 + BDG (N=12) cohort.

Budigalimab and ABBV-514 are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called treatment arms. The maximum-tolerated dose (MTD)/maximum administered dose (MAD) of ABBV-514 will be explored.